Heritage Investors Management Corp raised its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 182,043 shares of the company’s stock after acquiring an additional 1,571 shares during the quarter. Johnson & Johnson makes up about 1.4% of Heritage Investors Management Corp’s portfolio, making the stock its 18th biggest position. Heritage Investors Management Corp’s holdings in Johnson & Johnson were worth $26,555,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors also recently made changes to their positions in JNJ. Artemis Investment Management LLP boosted its position in shares of Johnson & Johnson by 887.1% in the 4th quarter. Artemis Investment Management LLP now owns 418,542 shares of the company’s stock worth $60,997,000 after purchasing an additional 376,142 shares in the last quarter. Corbenic Partners LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth $145,000. Atlantic Union Bankshares Corp boosted its position in shares of Johnson & Johnson by 1.1% in the 4th quarter. Atlantic Union Bankshares Corp now owns 100,946 shares of the company’s stock worth $14,725,000 after purchasing an additional 1,053 shares in the last quarter. Ballew Advisors Inc acquired a new stake in shares of Johnson & Johnson in the 4th quarter worth $202,000. Finally, First Command Bank boosted its position in shares of Johnson & Johnson by 1.9% in the 4th quarter. First Command Bank now owns 16,345 shares of the company’s stock worth $2,384,000 after purchasing an additional 308 shares in the last quarter. 67.28% of the stock is currently owned by institutional investors and hedge funds.
A number of analysts have recently weighed in on JNJ shares. Wells Fargo & Co raised their price objective on Johnson & Johnson from $155.00 to $165.00 and gave the stock an “overweight” rating in a research report on Thursday, January 9th. Atlantic Securities raised Johnson & Johnson from an “underweight” rating to a “neutral” rating in a research report on Wednesday, October 16th. Barclays raised Johnson & Johnson from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $140.00 to $173.00 in a research report on Thursday, December 19th. Morgan Stanley raised Johnson & Johnson from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $145.00 to $170.00 in a research report on Tuesday, December 17th. Finally, Sanford C. Bernstein raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $155.00 price target for the company in a research report on Friday, October 11th. Three research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. Johnson & Johnson has a consensus rating of “Buy” and a consensus target price of $159.33.
In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 2,017 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was sold at an average price of $141.07, for a total transaction of $284,538.19. Following the completion of the transaction, the executive vice president now owns 51,736 shares in the company, valued at approximately $7,298,397.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Hubert Joly acquired 5,000 shares of Johnson & Johnson stock in a transaction on Friday, December 13th. The shares were bought at an average price of $141.28 per share, with a total value of $706,400.00. Following the purchase, the director now directly owns 5,000 shares in the company, valued at approximately $706,400. The disclosure for this purchase can be found here. Insiders own 0.23% of the company’s stock.
Shares of JNJ opened at $146.52 on Wednesday. The stock has a 50-day moving average of $142.86 and a two-hundred day moving average of $134.74. Johnson & Johnson has a one year low of $125.00 and a one year high of $147.84. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. The stock has a market cap of $381.78 billion, a P/E ratio of 17.91, a P/E/G ratio of 2.33 and a beta of 0.71.
Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 EPS for the quarter, topping the Zacks’ consensus estimate of $2.00 by $0.12. Johnson & Johnson had a return on equity of 39.81% and a net margin of 21.09%. The company had revenue of $20.73 billion during the quarter, compared to analysts’ expectations of $20.14 billion. During the same quarter in the previous year, the firm posted $2.05 EPS. The firm’s revenue was up 1.9% compared to the same quarter last year. Analysts predict that Johnson & Johnson will post 8.66 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 25th will be given a dividend of $0.95 per share. The ex-dividend date is Monday, February 24th. This represents a $3.80 dividend on an annualized basis and a yield of 2.59%. Johnson & Johnson’s dividend payout ratio is currently 46.45%.
Johnson & Johnson Company Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: How Investors Can Profit from Options Trading
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.